



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Liang et al.

Serial No. 10/070,560

Filed: March 8, 2002

For: Method of Producing and Purifying
Endostatin Protein

)
)
) Art Unit: Not Yet Assigned
)
) Examiner: Not Yet Assigned
)
)
)
)


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.


This Supplemental Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be required. However, if a first Office Action on the merits has issued, please consider this Information Disclosure Statement under 37 C.F.R. 1.97(c). The Commissioner is hereby authorized to charge the applicable fees, if any, to Deposit Account No. 11-0855.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, DC 20231, on August 08, 2002


Jamie L. Greene - Reg. No. 32,467

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,



Jamie L. Greene
Reg. No. 32,467

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 05213-0551US (43170-258385)



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/070,560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	05213-0551US (43170-258385)

Sheet 1 of 7

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number ²	Kind Code ³ (if known)			
	1	00/80728		MELSON, JAMES A.	06/27/2000	

Examiner
Signature

Shulamith H. Shafer

Digitally signed by Shulamith H. Shafer
DN: cn=Shulamith H. Shafer, o=USPTO, ou=AO 104X,
email=sh.h.shafer@uspto.gov
Date: 2002.11.12 07:28:19 -0500

Date
Considered

11/12/2007

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/070,560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	05213-0551US (43170-258385)

Sheet 2 of 7

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/SHS/	2	Author: Title: Chapter 12: Vectors for Gene Therapy Publ: <u>Current Protocols in Human Genetics</u> Vol/Iss: Pages: Date: 1997	
	3	Author: BOUSSIF, O. et al. Title: A versatile vector for gene and oligonucleotide transfer into cells in culture and/or vivo: Polyethylenimine Publ: <u>Proc. Natl. Acad. Sci. USA</u> Vol/Iss: 92 Pages: 7297-7301 Date: 08/1995	
	4	Author: CALOS, MICHELE P. Title: The potential of extrachromosomal replicating vectors for gene therapy Publ: <u>TIG</u> Vol/Iss: 12 (11) Pages: 463-466 Date: 11/1996	
	5	Author: CHEN, P. et al. Title: Genetic Mechanisms of Tumor Suppression by the Human p53 Gene Publ: <u>Science</u> Vol/Iss: 250 Pages: 1576-1579 Date: 12/1990	
	6	Author: CHENG, PI-WAN Title: Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin Publ: <u>Human Gene Therapy</u> Vol/Iss: 7 Pages: 275-282 Date: 02/10/199	
	7	Author: CLAPP, C. et al. Title: The 16-kilodalton N-terminal Fragment Of Human Prolactin Is A Potent Inhibitor Of Angiogenesis Publ: <u>Endocrinology</u> Vol/Iss: 133 Pages: 1292-1299 Date: 03/01/93	
	8	Author: DAMERON, K.M. et al. Title: Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1 Publ: <u>Science</u> Vol/Iss: 265 Pages: 1582-1584 Date: 09/09/94	

Examiner
Signature

Shulamith H. Shafer

Copyright reported by Shulamith H. Shafer
100% own, Shulamith H. Shafer, a U.S. citizen, is the sole inventor of the invention disclosed herein.
Date: 09/11/2002 10:31:45 AMDate
Considered

11/12/2007

¹Unique citation designation number. ²See attached kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/070,560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	05213-0551US (43170-258385)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ^o
/SHS/	9	Author: DARDIK, R. et al Publ: <u>Eur J Biochem</u>	Title: The structure of endothelial cell thrombospondin - Characterization of the heparin-binding domains Vol/Iss: 168 (2) Pages: 347-355 Date: 10/15/198			
	10	Author: DEBS, R.J. et al. Publ: <u>The Journal of Biological Chemistry</u>	Title: Regulation of Gene Expression <i>In Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor Vol/Iss: 265 (18) Pages: 10189-10192 Date: 06/25/199			
	11	Author: DIXIT, V.M. et al. Publ: <u>Proc. Natl. Acad. Sci. USA</u>	Title: A monoclonal antibody against human thrombospondin inhibits platelet aggregation Vol/Iss: 82 Pages: 3472-3476 Date: 05/1985			
	12	Author: FAN et al. Publ: <u>Trends in Pharmacological Sciences</u>	Title: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Vol/Iss: 16 (2) Pages: 57-66 Date: 02/95			
	13	Author: FIDLER et al. Publ: <u>Cell</u>	Title: The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis Vol/Iss: 79(2) Pages: 185-188 Date: 10/21/94			
	14	Author: FUJIWARA, T. et al. Publ: <u>Cancer Research</u>	Title: Induction of Chemosensitivity in Human Lung Cancer Cells <i>In Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type <i>p53</i> Gene Vol/Iss: 54 Pages: 2287-2291 Date: 05/01/199			
	15	Author: GOLDMAN, C.K. et al. Publ: <u>Nature Biotechnology</u>	Title: <i>In vitro</i> and <i>in vivo</i> gene delivery mediated by a synthetic polycationic amino polymer Vol/Iss: 15 Pages: 462-466 Date: 05/1997			

Examiner
Signature

Shulamith H. Shafer

Digitally signed by Shadenath H. Shinde
DN: cn=Shadenath H. Shinde, o=IIS, ou=CSPTO, email=shadenath.shinde@perpita.gov
Date: 2002.11.12 02:40:15 +0500

Date
Considered

11/12/2007

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/070,560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	05213-0551US (43170-258385)

Sheet 4 of 7

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
/SHS/	16	Author: HAWKINS, MICHAEL J, M.D. Publ: <u>Current Opinion in Oncology</u> Title: Clinical trials of antiangiogenic agents	Vol/Iss: 7	Pages: 90-93	Date: 1995	
	17	Author: KING, RALPH P. Jr. Publ: <u>Wall Street Journal</u> Title: Novel Cancer Approach From Noted Scientist Hits Stumbling Block	Vol/Iss:	Pages: A1, A8	Date: 11/12/1999	
	18	Author: KOSFELD, M.D. et al. Publ: <u>The Journal of Biological Chemistry</u> Title: Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain on Human Thrombospondin	Vol/Iss: 268 (12)	Pages: 8808-8814	Date: 1993	
	19	Author: LESOON-WOOD, L.A. et al. Publ: <u>Human Gene Therapy</u> Title: Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Tumor in Nude Mice	Vol/Iss: 6	Pages: 395-405	Date: 04/1995	
	20	Author: MAIONE, T.E. et al. Publ: <u>Cancer Research</u> Title: Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity	Vol/Iss: 51	Pages: 2077-2083	Date: 04/15/1999	
	21	Author: MARSHALL, ELIOT Publ: <u>Science</u> Title: Gene Therapy's Growing Pains	Vol/Iss: 269	Pages: 1050-1055	Date: 08/25/1999	
	22	Author: MILLAUER, B. et al. Publ: <u>Nature</u> Title: Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant	Vol/Iss: 367	Pages: 576-579	Date: 02/10/94	

Examiner Signature

Shulamith H. Shafer

Digitally signed by Shulamith H. Shafer
DN: cn=Shulamith H. Shafer, ou=US, o=USPTO, email=shafer@uspto.gov
Date: 2002.11.12 12:52:45-0500Date
Considered

11/12/2007

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, this information collection is required to respond to a collection of information if it does not contain a valid OMB control number.

Complete if Known

Substitute for Form 1449/A/PTO				INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	
Sheet	5	of	7	Application No.	10/070,560
				Filing Date	03/08/2002
				First Named Inventor	Liang et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	05213-0551US (43170-258385)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/SHS	23	Author: O'REILLY et al. Title: Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma Publ: Cell Vol/Iss: 79 Pages: 315-328 Date: 10/21/94	
	24	Author: O'REILLY et al. Title: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth Publ: Cell Vol/Iss: 88 Pages: 277-285 Date: 01/24/97	
	25	Author: PARK et al. Title: Development of liposome- and anti-HER2 immunoliposome/plasmid complexes for efficient and selective gene therapy Publ: Proceedings of the American Association for Cancer Research Vol/Iss: 38 Pages: 342 Date: 03/1997	
	26	Author: PASQUALINI, R. et al. Title: αv Integrins as receptors for tumor targeting by circulating ligands Publ: Nature Biotechnology Vol/Iss: 15 Pages: 542-546 Date: 06/1997	
	27	Author: PASQUALINI, R. et al. Title: Organ targeting <i>in vivo</i> using phage display peptide libraries Publ: Nature Vol/Iss: 380 Pages: 364-166 Date: 03/28/199	
	28	Author: SAIKI et al. Title: Inhibition of Tumor Angiogenesis by a Synthetic Cell-adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD) Publ: Jpn. J. Cancer Research Vol/Iss: 81 Pages: 668-675 Date: 1990	
	29	Author: SAKAMOTO, N. et al. Title: Inhibition of Angiogenesis And Tumor Growth By A Synthetic Laminin Peptide. Cdpgyigr-nh2 Publ: Cancer Research Vol/Iss: 51 Pages: 903-906 Date: 02/01/91	

Examiner
Signature

Shulamith H. Shafer

Copyright reported by Shulamith H. Shafer
US Pat. & Trademark Office, P.O. Box 1000, Alexandria, VA 22304-1000
Date: 11/12/02 4:10:00 PMDate
Considered

11/12/2007

¹Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/070,560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	05213-0551US (43170-258385)

Sheet 6 of 7

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/SHS/	30	Author: SHEIKH et al. Title: Overexpression of p21/WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines Publ: Oncogene Vol/Iss: 11 Pages: 1899-1905 Date: 1995	
	31	Author: TANAKA, T. et al. Title: Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits angiogenesis and tumor growth Publ: Nature Medicine Vol/Iss: 3 Pages: 437-442 Date: 04/1997	
	32	Author: TOLSMA, S.S. et al. Title: Peptides Derived From Two Separate Domains Of The Matrix Protein Thrombospondin-1 Have Antiangiogenic Activity Publ: Journal of Cell Biology Vol/Iss: 122 Pages: 497-511 Date: 07/1993	
	33	Author: WEINSTAT-SASLOW, D.L. et al. Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Angiogenesis Publ: Cancer Research Vol/Iss: 54 Pages: 6504-6511 Date: 1994	
	34	Author: XU, M. et al. Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes Publ: Molecular Genetics and Metabolism Vol/Iss: 64 Pages: 001-005 Date: 1998	
	35	Author: XU, M. et al. Title: Gene Therapy with P53 and a Fragment of Thrombospondin 1 Inhibits Human Breast Cancer <i>In Vivo</i> Publ: Molecular Genetics and Metabolism Vol/Iss: 63 Pages: 103-109 Date: 1998	
↓	36	Author: XU, M. et al. Title: Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity Publ: Human Gene Therapy Vol/Iss: 8 Pages: 177-185 Date: 01/20/199	


Examiner
Signature

Shulamith H. Shafer

Digitally signed by Shulamith H. Shafer
DN: cn=Shulamith H. Shafer, o=USPTO, ou=USPTO, email=shs@uspto.gov
Date: 2002.11.12 12:42:30 -0500Date
Considered

11/12/2007

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO				<div style="text-align: center;">  </div>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application No.	10/070,560	
				Filing Date	03/08/2002	
				First Named Inventor	Liang et al.	
				Group Art Unit	Not Yet Assigned	
				Examiner Name	Not Yet Assigned	
Sheet 7 of 7				Attorney Docket Number 05213-0551US (43170-258385)		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
/SHS/	37	Author: ZABRENETZKY, V. et al. Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT PROGRESSION IN MELANOMA LUNG AND BREAST CARCINOMA CELL Publ: Int. J. Cancer Vol/Iss: 59 Pages: 191-195 Date: 1994				
/SHS/	38	Author: ZHU, N. et al. Title: Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice Publ: Science Vol/Iss: 261 Pages: 209-211 Date: 07/09/199				

Examiner Signature	Shulamith H. Shafer	Date Considered	11/02/2007
--------------------	---------------------	-----------------	------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.